Is Olverembatinib a targeted therapy drug?

Yes, Olverembatinib is a targeted therapy drug classified as a tyrosine kinase inhibitor. It exerts specific action on designated molecular targets (e.g., BCR-ABL fusion protein) to inhibit cancer cell proliferation.